Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome

ClinicalTrials.gov ID: NCT00919113

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00919113. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Randomized, Double-Blind, Parallel Group Evaluation of the Effectiveness and Safety of Uracyst® Compared to Inactive Control in Subjects With Interstitial Cystitis/Painful Bladder Syndrome

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A new device for interstitial cystitis is compared to inactive control to determine if it is safe and effective. The study lasts approximately 7 weeks with a 19-week follow-up period.

Study identification

NCT ID: NCT00919113
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Watson Pharmaceuticals; Industry
Enrollment: 98 participants

Conditions and interventions

Conditions

Interventions

2% sodium chondroitin sulfate Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 2009 (Type not available)
Primary completion: Dec 2010 (Actual)
Completion: Dec 2010 (Actual)
Last update posted: May 3, 2013

2009 – 2010

United States locations

U.S. sites: 20
U.S. states: 14
U.S. cities: 20

Facility	City	State	ZIP	Site status
Not listed	Boulder	Colorado	80304	—
Not listed	Denver	Colorado	80211	—
Not listed	Farmington	Connecticut	06032	—
Not listed	Plantation	Florida	33317	—
Not listed	Wellington	Florida	33414	—
Not listed	Columbus	Georgia	31904	—
Not listed	Coeur d'Alene	Idaho	83814	—
Not listed	Evanston	Illinois	60201	—
Not listed	Melrose Park	Illinois	60160	—
Not listed	Royal Oak	Michigan	48073	—
Not listed	Las Vegas	Nevada	89148	—
Not listed	Englewood	New Jersey	07601	—
Not listed	Sewell	New Jersey	08080	—
Not listed	Woodlane	New Jersey	08060	—
Not listed	Albany	New York	12206	—
Not listed	Poughkeepsie	New York	12601	—
Not listed	Winston-Salem	North Carolina	27103	—
Not listed	Oklahoma City	Oklahoma	73104	—
Not listed	Philadelphia	Pennsylvania	19104	—
Not listed	Mountlake Terrace	Washington	98043	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00919113, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 3, 2013 · Synced Nov 14, 2026